DOCSLIB.ORG

Pharmaceutical Company Contact Information - Rebate Filing - As of March 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical Company Contact Information - Rebate Filing - As of March 2015 Pharmaceutical Company Contact Information - Rebate Filing - as of March 2015 Labeler Name Invoice Contact Phone 00002 LILLY USA, LLC LISA NORTON (317)276-2000 00003 ER SQUIBB AND SONS INC. LYNN LEWIS 6098974731 00004 GENENTECH CONTRACT ADMINISTRATION (650)225-6735 00006 MERCK & CO., INC. DOUG BICKFORD (215)652-0671 00007 SMITHKLINE BEECHAM DAVID BUCKLEY 2157515690 00009 PHARMACIA AND UPJOHN COMPANY ANNA MULLIGAN (901)215-1814 00013 PHARMACIA AND UPJOHN COMPANY ANNA MULLIGAN (901)215-1814 00015 MEAD JOHNSON AND COMPANY LYNN LEWIS 6098974731 00023 ALLERGAN INC SHOBHANA MINAWALA 7142466205 00024 SANOFI WINTHROP PHARMACEUTICALS LAURIE DUNLAP, ADMIN., GOVT. OPERATIONS 2125514198 00025 PHARMACIA CORPORATION MONA BASS (901)215-1814 00029 SMITHKLINE BEECHAM DAVID BUCKLEY 2157515690 00032 SOLVAY PHARMACEUTICALS STACEY LENOX (847)937-3979 00045 MCNEIL PHARMACEUTICAL 9082186777 00049 PFIZER-ROERIG JOE DELUCA (901)215-1814 00051 UNIMED PHARMACEUTICALS, INC STACY LENOX (847)937-3979 00052 ORGANON, USA, INC. 9733254500 00054 ROXANE LABORATORIES, INC. VICKEY ARIAS 615-431-0793 00056 DUPONT PHARMACEUTICALS LYNN LEWIS 3028921134 00062 JOHNSON & JOHNSON HEALTH CARE SYSTEMS (908)218-6466 00065 ALCON LABORATORIES, INC. DEBBIE NIXON, MNGR GOV'T PRICING & REBA (817)568-6231 00066 AVENTIS PHARMACEUTICALS MATTHEW MUELLER (908)981-7461 00067 NOVARTIS CONSUMER HEALTH, INC. 9737816101 00069 PFIZER LABORATORIES DIV OF PFIZER INC ANNA MULLIGAN (901)215-1814 00071 PARKE-DAVIS DIV OF PFIZER, INC. ANNA MULLIGAN (901)215-1814 00074 ABBVIE US LLC AMANDA TUCKER 847-938-8970 00075 AVENTIS PHARMACEUTICALS JOE DELPONTE 9082437770 00078 NOVARTIS PHARMACEUTICALS CORPORATION BONNIE SHARKEY 8627788094 00085 MERCK SHARP & DOHME CORP. ELAINE CARTER 9086532851 00087 BRISTOL-MYERS SQUIBB COMPANY LYNN LEWIS 6098974758 00088 AVENTIS PHARMACEUTICALS JOE DELPONTE 9082437770 00089 GRACEWAY PHARMACETICALS (267)948-0430 00091 SCHWARZ PHARMA KREMERS URBAN COMPANY LAKESHA INGRAM (770)970-8229 00093 LEMMON COMPANY LISA PEPE 00115 GLOBAL PHARMACEUTICAL CORPORATION (215)558-4349 00116 XTTRIUM LABORATORIES, INC. VIJAY VERMA (773)568-5800 00121 PHARMACEUTICAL ASSOCIATES, INC. JANICE THOMAS 00126 COLGATE ORAL PHARMACEUTICALS SUSAN J. DIGIROLAMO Page 1 of 6 00131 SCHWARZ PHARMA MANUFACTURING LAKESHA INGRAM (770)970-8229 00140 ROCHE LABORATORIES ADRIANNA ARANDA (650)225-6735 00143 WEST-WARD PHARMACEUTICAL CORP SILVANA SANTIAGO (732)542-1191 00168 E FOUGERA AND CO, DIV OF ALTANA INC (631)719-3051 00172 ZENITH LABORATORIES, INC LISSA PEPE 3055754186 00173 GLAXO WELLCOME INC. DAVID BUCKLEY 9194837942 00182 GOLDLINE LABORATORIES INC LISA PEPE 3055754222 00185 EON LABS MANUFACTURING, INC. 862-778-0274 00186 ASTRAZENECA LP DAVID WRIGHT (302)886-7598 00228 ACTAVIS ELIZABETH LLC EVELYN BIGGIERS 862-261-7260 00258 INWOOD LABORATORIES INC JULIA FUEHRMEYER (314)513-6092 00281 SAVAGE LABORATORIES, DIV OF ALTANA INC DANIEL WOOD (631)719-3051 00299 GALDERMA LABORATORIES, INC. DONNA BRUNSON 8179615188 00310 ASTRAZENECA LP DAVID WRIGHT (302)886-7598 00378 MYLAN PHARMACEUTICALS, INC. LYNN MIHALIK (800)826-9526 00406 MALLINCKRODT INC. (314)654-6226 00409 AP PHARMACEUTICALS, INC. DEBRA L. DEYOUNG 8479376982 00430 WARNER CHILCOTT LABORATORIES 9734423262 00456 FOREST PHARMACEUTICALS INC (314)513-6092 00462 PHARMADERM, DIV OF ALTANA INC DANIEL WOOD (631)719-3051 00472 ACTAVIS MID ATLANTIC LLC (862)261-7000 00496 FERNDALE LABORATORIES INC. DARLEEN SEXTON 2485480279 00517 AMERICAN REGENT LABORATORIES, INC. MARY JANE HELENEK 00536 RUGBY LABORATORIES INC MICHELE SOLIMO, SUPERVISOR 00555 DURAMED BARR LABS ROBERT VARASANO 2019303456 00574 PADDOCK LABORATORIES, INC. LINDA ZAHLER 6125464676 00591 WATSON PHARMA PATRICIA GASPER 862-261-7260 00597 BOEHRINGER INGELHEIM PHARMACEUTICALS SUSAN ECHAVARRIA 615-431-0793 00703 GENSIA LABORATORIES, LTD. LISA PEPE 7144572814 00713 G AND W LABORATORIES INC MARY LOU ULAKY 00781 GENEVA PHARMACEUTICALS, INC., 862-778-0274 00884 PEDINOL PHARMACAL INC RICHARD STRAUSS 5162939500 00904 MAJOR PHARMACEUTICALS SAMIR SHAH 3135258700 00944 HYLAND IMMUNO MEDICAID REBATES 8479483939 00955 KANETTA PHARMACAL LAURIE DUNLAP 2125514198 00998 ALCON -PUERTO RICO- INC. JOHN CAYWOOD (817)568-6231 08881 SHERWOOD MEDICAL 10019 BAXTER HEALTHCARE CORPORATION 10139 GENERAMEDIX, INC. CHRISTINE CANNON (908)504-1341 10147 PATRIOT PHARMACEUTICALS,LLC (732)562-3771 10337 DOAK DERMATOLOGICS DANIEL WOOD (631)719-3051 Page 2 of 6 10370 ANCHEN PHARMACEUTICALS, INC. PATRICIA PELAEZ (201)802-4167 10631 RANBAXY PHARMACEUTICALS, INC. BERT SULLIVAN 11042 ADVANCIS PHARMACEUTICAL CORPORATION ROBERT C. LOW (301)946-6690 11980 ALLERGAN INC SHOBHANA MINAWALA 7142466205 12496 RECKITT BENCKISER RYAN MCGOVERN (000)000-0000 13310 AR SCIENTIFIC 13533 TALECRIS BIOTHERAPEUTICS, INC. 13668 TORRENT PHARMACEUTICALS KASONDRA FERRIS (269)544-2299 13913 DEPOMED (501)744-8000 14290 PRECISION DERMATOLOGY (888)713-8154 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED EVELYN BIGGIERS 862-261-7260 15338 APACE PACKAGING, LLC SHANNON BELL (270)590-0356 15584 GILEAD SCIENCES, INC. SUSAN KWAN 15686 MIDLAND HEALTHCARE, LLC RAMAN KAPUR (609)452-2700 16252 COBALT LABORATORIES, INC EVELYN BIGGIERS (862)261-7260 23155 HERITAGE PHARMACEUTICALS, INC. AMANDA REBNICKY (732)429-1000 24208 BAUSCH & LOMB PHARMACEUTICALS, INC. (813)866-2012 25010 ATON PHARMA, INC. ED COLLINS (973)887-1664 28105 HILL DERMACEUTICALS, INC. BOB WISE 4073231887 29033 NOSTRUM LABORATORIES, INC. FRANK C. ANN (816)308-4905 29336 GRACEWAY PHARMACEUTICALS, LLC JOHN BLISS, MNGR CONTRACT MANAGEMENT (267)948-0430 31722 CAMBER PHARMACEUTICALS MEGAN HINMAN (732)377-2029 37205 LEADER BRAND PRODUCTS TIMOTHY J. DOYLE, MERCHANDISE MANAGER 6147177244 39822 X-GEN PHARMACEUTICALS 41616 SUN PHARMA GLOBAL, INC. ANAND SHAH (313)871-8400 42023 JHP PHARMACUETICALS LLC (973)658-3555 42043 KARALEX PHARMA, LLC (201)529-0402 42192 ACELLA PHARMACEUTICALS, LLC KA ARORA (678)325-5189 42769 ANIP ACQUISITION COMPANY DARLENE SACCOMAN (218)634-3639 42806 EPIC PHARMA, LLC NEKELA BORNELL (718)276-8607 42858 RHODES PHARMACEUTICALS, LP KATYE GEMMA (401)262-9417 42998 MARATHON PHARMACEUTICALS JIM SHARPLES (866)945-7860 43063 PDRX PHARMACEUTICALS, INC. JACK MCCALL (405)942-3040 43199 COUNTY LINE PHARMACEUTICALS, LLC LISA SCHUMACHER (262)439-8109 43386 GAVIS PHARMACEUTICALS, LLC ARSHAD KAGALWALLA (908)603-6007 43478 ROUSES POINT PHARMACEUTICALS LLC JANE O'BRIEN (630)632-2427 43547 SOLCO HEALTHCARE US, LLC SHAFI RAHMAN (714)513-1000 43598 DR. REDDY'S LABORATORIES MANUELA BANDEIRA (908)203-4960 44183 MACOVEN PHARACEUTICALS, INC. JAMEY ROBERTS (229)726-6047 45802 CLAY-PARK LABS INC REBECCA STRATTON (269)686-1905 Page 3 of 6 45963 ACTAVIS, INC. BOB MIRANDA 862-261-7260 46672 MIKART INC. LARRY GUNNIN 4043514510 46987 ACTAVIS KADIAN LLC BOB MIRANDA 862-261-7260 47335 SUN PHARMA GLOBAL FZE ANAND SHAH (313)556-4115 48102 FERA PHARMACEUTICALS, LLC CECILIA CARFORA (516)277-1449 49158 THAMES PHARMACAL COMPANY, INC. PAULA FIERRO 5167371155 49502 DEY LABORATORIES JEREMY MASSETT 49702 VIIV HEALTHCARE CO. DAVID BUCKLEY (215)751-4589 49708 CARACO PHARMA, INC. ANAND SHAH (313)556-4115 49884 PAR PHARMACEUTICAL INC JOSEPH C. SCHOTT 9145735527 49938 JACOBUS PHARMACEUTICALS CO INC. DAVID P. JACOBUS M.D. 6099217447 49999 QUALITY CARE PRODUCT, LLC JEANNIE SIEREN (734)847-3847 50111 BARR LABORATORIES INC. LISA PEPE 9735994004 50383 HI-TECH PHARMACAL CO. INC., THEODORE DIAMONT 50419 BERLEX LABORATORIES, INC., (866)939-4938 50458 JOHNSON & JOHNSON HEALTHCARE SYSTEMS 9082186777 50474 UCB PHARMA JUDY SZATKOWSKI (770)970-8793 50742 INGENUS PHARMACEUTICALS, LLC MATTHEW BAUMGARTNER (407)354-5365 51285 DURAMED PHARMACEUTICALS INC. CRISTINA CONVERY (201)930-3785 51672 TARO PHARMACEUTICALS INC. LISA KACHNIC 51991 BRECKENRIDGE INC. MARY LESCANO (800)367-3395 52054 AMEDRA PHARMACEUTICALS LOUIS PASTOR (732)868-1090 52152 ACTAVIS TOTOWA LLC EVELYN BIGGIERS (973)889-6650 52244 ACTIENT PHARMACEUTICALS KATHY MARIE BLECHA (913)669-7066 52544 WATSON LABORATORIES, INC. EVELYN BIGGIERS (862)261-7260 53489 MUTUAL PHARMACEUTICAL COMPANY ROSEMARIE O'MALLEY, PRICING COORDINATOR 2152886500 53746 AMNEAL PHARMACEUTICALS, LLC ROBERTA BRYANT (631)952-0214 54458 INTERNATIONAL LABS, INC. JAKE KEENAN (414)434-4630 55111 DR. REDDY'S LABORATORIES, INC. MANUELA BANDEIRA (908)203-4960 55289 PDRX PHARMACEUTICAL 55390 BEDFORD LABORATORIES MIKE FALK 55513 AMGEN INC. PEGGY WATSON-MEINKE (805)447-2324 57664 CARACO PHARMACEUTICAL LABORATORIES LTD JEAN HEIDER 3138718400 57844 GATE PHARMACEUTICALS LISA PEPE 58160 GLAXO SMITHKLINE DAVID BUCKLEY 58177 ETHEX CORPORATION 58864 PDRX PHARMACEUTICAL 59011 PURDUE PHARMA, L.P. JUNE STOWE 2038998035 59148 OTSUKA AMERICA KAELYN DECONTI (919)463-1990 59310 WAKEFIELD PHARMACEUTICALS, INC. LISA PEPE 7706641661 Page 4 of 6 59676 ORTHO BIOTECH INC. RADHIKA VENUGOPAL, MANAGER (908)218-6466 59746 CADISTA 59762 GREENSTONE LLC ANNA MULLIGAN (901)215-1814 59767 DIGESTIVE CARE, INC. W. T. HUMPHRIES 6108616946 60258 CYPRESS PHARMACEUTICAL, INC. MAX DRAUGHN 8008564393 60429 GOLDEN STATE MEDICAL SUPPLY, INC. JIM STROUD 8052958101 60432 MGP - MORTON GROVE PHARMACEUTICALS, INC (847)410-6759 60505 APOTEX USA INC. JASON GENSBURGER 9543494211 60758 PACIFIC PHARMA MARY BERG 8003474500 60793 PFIZER LABORATORIES DIV PFIZER INC ANNA MULLIGAN (901)215-1814 61442 CARLSBAD TECHNOLOGY, INC. MICHAEL HSIAO (760)431-8284 61570 MONARCH PHARMACEUTICAL CORPORATION 61748 VERSAPHARM CARL A. MERIDETH (770)499-8100 61958 GILEAD SCIENCES, INC. SUSAN KWAN 8009399009 62037 WATSON PHARMA, INC. ULLI BEERMANN 862-261-7260 62175 KREMERS URBAN LAKESHA INGRAM (970)770-8229 62584 AMERICAN HEALTH
Load more

Recommended publications
  • Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000
    uniQure N.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands +1-339-970-7000 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on September 14, 2017 To the Shareholders of uniQure N.V.: Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Extraordinary Meeting”) of uniQure N.V., a public company with limited liability ( naamloze vennootschap ) under the laws of the Netherlands (the “Company,” “uniQure,” and “we”), will be held on September 14, 2017, at 9:30 a.m., Central European Summer Time, at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP Amsterdam, the Netherlands, for the following purposes: I. Opening and announcements; II. Appointment of Jeremy P. Springhorn, Ph.D. as a non-executive director (voting proposal no. 1); III. Appointment of Madhavan Balachandran as a non-executive director (voting proposal no. 2); IV Any other business that may properly come before the meeting or any adjournment of the meeting; and V. Closing of the meeting. Each person authorized to attend the Extraordinary Meeting may inspect the Agenda at the office of uniQure. Our Board of Directors (our “Board”) recommends that you vote “FOR” each of the voting proposals noted above. The record date is set at the close of business on August 17, 2017 EST and, therefore, only the Company’s shareholders of record at the close of business on August 17, 2017 EST are entitled to receive this notice (this “Notice”) and to vote at the Extraordinary Meeting and any adjournment thereof. Only shareholders who have given notice in writing to the Company by September 12, 2017 of their intention to attend the Extraordinary Meeting in person are entitled to attend the Extraordinary Meeting in person.
    [Show full text]
  • Essex Hangar Aircrafi: Challenger (Schering Plough) Tail Number: N34CD Flight Time: 50 Minutes
    This document is from the collections at the Dole Archives, University of Kansas http://dolearchives.ku.edu ... DRAFT# 1- 8/26/94 ·- Contact: Mo Taggart 703/684-7848 Jo-Anne Coe 703/845-1714 SENATOR DOLE SCHEDULE ~ AUGUST 30, 1994 -NEW YORK TUESDAY. AUGUST 30 .. 1".4 10:35 am DEPART Capitol for National Airport Ori ver: Wilbert 10:50 am ARRIVE National Airport and proceed to departing aircraft PBO: Signature 703/419·8440 10:55 am DEPART Wushington for Morristown, NJ FBO: Essex Hangar Aircrafi: Challenger (Schering Plough) Tail number: N34CD Flight time: 50 minutes Pilots: Curt Barsi John Santucci Seats: 6 Meal: None Manifest: Senator Dole Rob Lively, Schcring Plough Mike Glassner • Mark Miller Contact: Rob Lively 202/463-8809 11:45 am ARRIVE Morristown, NJ FBO: Essex Hangar 201/539-6554 11 :50 am DEPART airport for Shering Plough Headquarters Driver: Mr. Luciano's driver Drive time: 5 minutes J,ocation: l Giralda Fanns Madison, NJ 11 :55 am ARRIVE Schering Plough Headquarters 20 I /822-7440 Page 1 of 48 This document is from the collections at the Dole Archives, University of Kansas http://dolearchives.ku.edu TUESDAY, AUGUSI-.3D .1994 PAGE TWO 12:00 N- ATTEND Lunch with Bob Luciano, Chairman of Schering Plough 1:30 pm 1:30 pm DEPART Schering Plough Headquarters for airport Driver: Mr. Luciano's driver Drive time: 5 minutes 1:35 pm ARRIVE airport and proceed to departing heliocopter FBO: Essex Hangar 201/539-6554 1:40 pm DEPART Morristown, NJ for New York Helo pad: 34th Strecf Helo pad Aircraft: S-76 .
    [Show full text]
  • Transcept Pharmaceuticals, Inc
    Table of Contents SCHEDULE 14A (RULE 14A 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by x Definitive Proxy Statement Rule 14a-6(e)(2)) ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 Transcept Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents NOTICE OF ANNUAL MEETING OF STOCKHOLDERS JUNE 23, 2011 To Our Stockholders: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Transcept Pharmaceuticals, Inc., a Delaware corporation, will be held on Thursday, June 23, 2011, at 8:30 a.m., local time, at our office located at 1003 West Cutting Blvd., Suite 110, Point Richmond, California 94804, for the following purposes: 1.
    [Show full text]
  • CB2013 Committee and Board Disclosureauditlist 9.10.13
    2013-2014 Conflict of Interest Disclosure AST Activity Participant First Name Participant Last Name Degree DisclosureDate Disclsoure Item Committee Member Reza Abdi MD 4/22/2013 No Relevant Financial Relationships Committee Member Sameh R. Abul-Ezz MD, PhD 4/16/2013 No Relevant Financial Relationships Committee Member Deborah B. Adey MD 4/15/2013 No Relevant Financial Relationships Committee Member Enver Akalin MD 4/16/2013 Consultant relationship with Pfizer Fellows 2013 Maria-Luisa Alegre MD, PhD 7/12/2013 No Relevant Financial Relationships Committee Member Alessandrini Alessandro PhD 4/29/2013 No Relevant Financial Relationships Board Member James S. Allan MD 5/3/2013 Committee Member No Relevant Financial Relationships Rita R. Alloway PharmD, FCCP Grant Support relationship with Astellas Grant Support relationship with BMS Grant Support relationship with Novartis Grant Support relationship with Lifecycle Grant Support relationship with Millenium Grant Support relationship with Pfizer (previously Wyeth) Grant Support relationship with Genentech (previously Roche) Board Member Grant Support relationship with Viropharma Committee Member Grant Support relationship with Alexion Fellows 2013 7/18/2013 Grant Support relationship with Sanofi (previously Genzyme, previously Sangstat) Committee Member Sandra Amaral MD, MHS 6/18/2013 Other relationship with Bristol Myers-Squibb Hatem Amer MD 5/6/2013 Grant Support relationship with Abbott Laborartories. Committee Member Other relationship with Massacheussetts Medical Society. Committee Member William Applegate No Relevant Financial Relationships Committee Member Alexander Aussi BSN, RN, MBA 4/22/2013 Consultant relationship with Total Transplant Advantage, LLC Committee Member Jamil Azzi MD 4/30/2013 No Relevant Financial Relationships Committee Member Fellows 2013 Mark L.
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • Surescripts, Llc As Amicus Curiae in Support of Petitioners in No
    Nos. 19-508 and 19-825 In the Supreme Court of the United States ———————————— AMG CAPITAL MANAGEMENT, LLC, ET AL., Petitioners, v. FEDERAL TRADE COMMISSION, Respondent. ———————————— FEDERAL TRADE COMMISSION, Petitioner, v. CREDIT BUREAU CENTER, LLC, ET AL., Respondents. ———————————— ON WRITS OF CERTIORARI TO THE UNITED STATES COURTS OF APPEALS FOR THE SEVENTH AND NINTH CIRCUITS ———————————— BRIEF OF SURESCRIPTS, LLC AS AMICUS CURIAE IN SUPPORT OF PETITIONERS IN NO. 19-508 AND RESPONDENTS IN NO. 19-825 ———————————— ALFRED C. PFEIFFER, JR. ROMAN MARTINEZ LATHAM & WATKINS LLP Counsel of Record 505 Montgomery Street AMANDA P. REEVES Suite 2000 ALLYSON M. MALTAS San Francisco, CA 94111 DOUGLAS C. TIFFT BLAKE E. STAFFORD JAMES A. TOMBERLIN* LATHAM & WATKINS LLP 555 Eleventh Street, NW Suite 1000 Washington, DC 20004 (202) 637-2200 [email protected] Counsel for Amicus Curiae Surescripts, LLC TABLE OF CONTENTS Page TABLE OF AUTHORITIES ...................................... ii INTEREST OF AMICUS CURIAE ............................1 SUMMARY OF ARGUMENT .....................................3 ARGUMENT ...............................................................5 I. The FTC Has Increasingly Wielded Section 13(b) To Obtain Monetary Relief In Antitrust Cases ................................................5 II. The FTC’s Antitrust Authority Confirms That Section 13(b) Does Not Authorize Monetary Relief ..................................................22 CONCLUSION ..........................................................32 ii TABLE OF AUTHORITIES Page(s) CASES Apple Inc. v. Pepper, 139 S. Ct. 1514 (2019) .......................................... 13 Armstrong v. Exceptional Child Center, Inc., 575 U.S. 320 (2015) .............................................. 23 Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) .............................................. 26 In re Cardinal Health, Inc., No. 101-0006, 2015 WL 1849040 (F.T.C. Apr. 17, 2015) ........................ 19, 20, 28, 30 Credit Suisse Securities (USA) LLC v. Billing, 551 U.S.
    [Show full text]
  • 2020 Annual Report Products
    Products 2020 Annual Report From the CEO Dear Fellow Shareholders, Perrigo’s transformation to a pure-play Consumer Self-Care Company has come a long way LQMXVWWZRVKRUW\HDUV:HKDYHUHVWRUHGVXVWDLQDEOHWRSOLQHJURZWKGHOLYHUHGRQRXU¿QDQFLDO SURPLVHVUHFRQ¿JXUHGRXUSRUWIROLRRIEXVLQHVVHVXSGDWHGWKH,7LQIUDVWUXFWXUHDQGSURFHVVHV of the Company, expanded capacity, upgraded leadership talent, installed business intelligence capabilities, built a new product pipeline of over $500 million and re-instilled a sense of pride and energy among our 11,000 team members. Making this even more remarkable, is that we kept the WUDQVIRUPDWLRQRQWUDFNLQWKHIDFHRIWKHJOREDO&29,'SDQGHPLF,KRSH\RXDUHDVSURXGRI3HUULJR¶VJOREDOWHDP DV,DPIRUKRZWKH\ZRUNHGWRNHHSHDFKRWKHUVDIHNHSWRXUHVVHQWLDOSURGXFWVÀRZLQJDQGNHSWRXUWUDQVIRUPDWLRQ to a consumer self-care company on track through all of the personal and professional uncertainty that came their way LQ7KH\DUHKHURHV As a result of their efforts, Perrigo delivered strong net sales growth for the second year in a row in 2020 and World-wide Consumer sales reached a new record high. Equally important, the team stabilized adjusted operating income after a few years of decline even as we invested over $50 million in our business and overcame $35 million RIXQSODQQHGKHDGZLQGVGXHSULPDULO\WR&29,'UHODWHGVDIHW\FRVWVDQGEXVLQHVVLPSDFWIURPWKHZHDNFROG FRXJKDQGÀXVHDVRQUHODWHGWR&29,'¶VLPSDFWRQSXEOLFOLIH$OOLQDOOZHKDGDYHU\VWURQJ\HDU Our transformation efforts reached an essential milestone after the year closed when we announced the sale of RXU3UHVFULSWLRQ3KDUPDFHXWLFDOVEXVLQHVVWR$OWDULV&DSLWDO3DUWQHUV//&7KHWUDQVDFWLRQUHLQIRUFHVRXUDELOLW\
    [Show full text]
  • Federal Register/Vol. 84, No. 232/Tuesday, December 3, 2019
    Federal Register / Vol. 84, No. 232 / Tuesday, December 3, 2019 / Notices 66191 the Assistant Attorney General, patterns, devices, manufacturing filed with and accepted, subject to final developed the HSR Rules and the processes, or customer names. approval, by the Commission, has been corresponding Notification and Report placed on the public record for a period Form. Heather Hippsley, of thirty (30) days. The following On September 11, 2019, the Deputy General Counsel. Analysis to Aid Public Comment Commission sought comment on the [FR Doc. 2019–26075 Filed 12–2–19; 8:45 am] describes the terms of the consent reporting requirements associated with BILLING CODE 6750–01–P agreement and the allegations in the the HSR Rules and corresponding complaint. An electronic copy of the Notification and Report Form. 84 FR full text of the consent agreement 47951. No relevant comments were FEDERAL TRADE COMMISSION package can be obtained from the FTC received. Pursuant to the OMB [File No. 191 0061] Home Page (for November 15, 2019), on regulations, 5 CFR part 1320, that the World Wide Web, at https:// implement the PRA, 44 U.S.C. 3501 et Bristol-Myers Squibb Company and www.ftc.gov/news-events/commission- seq., the FTC is providing this second Celgene Corporation; Analysis of actions. opportunity for public comment while Agreement Containing Consent Orders You can file a comment online or on seeking OMB approval to renew the pre- To Aid Public Comment paper. For the Commission to consider existing clearance for those information your comment, we must receive it on or collection requirements.
    [Show full text]
  • CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under §240.14a-12 CONCERT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Concert Pharmaceuticals, Inc.
    [Show full text]
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry
    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
    [Show full text]
  • 2014.10.22-110Cv00528-Pfizer-Etal
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., PHARMACIA & UPJOHN ) COMPANY, PHARMACIA & UP JOHN ) COMPANY LLC, SUGEN, INC., C.P .. ) PHARMACEUTICALS INTERNATIONAL ) C.V., PFIZER PHARMACEUTICALS LLC, ) C.A. No. 10-528-GMS and PF PRISM C.V., ) ) Plaintiffs, ) ) v. ) ) MYLAN PHARMACEUTICALS INC., ) ) Defendant. ) _______________________________ ) MEMORANDUM I. INTRODUCTION In this patent infringement action, plaintiffs Pfizer Inc., Pharmacia & Upjohn Company, Pharmacia & Upjohn Company LLC, Sugen, Inc., C.P. Pharmaceuticals International C.V., Pfizer Pharmaceuticals LLC, and PF Prism C.V. (collectively, "Pfizer") allege that pharmaceutical products proposed by defendant Mylan Pharmaceuticals Inc. ("Mylan") infringe the asserted claims of the patents-in-suit. (D.I. 1.) The court held a four-day bench trial in this matter on November 26 through November 29, 2012. (D.I. 148-151.) Presently before the court are the parties' post-trial proposed findings of fact and conclusions of law concerning the validity of the patents-in-suit, specifically whether the asserted claims are invalid as obvious under 35 U.S.C. § 103. (D.I. 152, 153.) Pursuant to Federal Rule of Civil Procedure 52( a), and after having considered the entire record in this case and the applicable law, the court concludes that: (1) all asserted claims ofthe patents-in-suit are not invalid due to obviousness; and (2) Pfizer's Rule 52(c) motion is granted, and Mylan's Rule 52( c) motion is denied. These findings of fact and conclusions oflaw are set forth in further detail below. II. FINDINGS OF FACT 1 A. The Parties 1. Plaintiff Pfizer Inc.
    [Show full text]
  • Salix Pharmaceuticals, Inc. 2007 Annual Report and Form 10-K
    2007 Annual Report and Form 10-K Advancing Treatment in GastroenterologyTM Corporate Mission Statement Salix is committed to being the leading U.S. specialty pharmaceutical Company licensing, developing and marketing innovative products to health care professionals to prevent or treat gastrointestinal disorders in patients while providing rewarding opportunities for our employees and creating exceptional value for our stockholders. To Our Stockholders Despite the December 28, 2007 approval of three generic delivery of mesalamine, or 5-ASA, beginning in the small balsalazide products by the Office of Generic Drugs, Salix bowel and continuing throughout the colon. Wilmington succeeded in making substantial advances in its business Pharmaceuticals, which licensed metoclopramide-ZYDIS to during 2007. From a product development standpoint we us, is moving forward in seeking FDA approval to market made impressive strides toward accessing both the multi- this fast-dissolving formulation. At this time, Wilmington is billion dollar irritable bowel syndrome market as well as targeting a fourth quarter 2008 approval. We believe that the hepatic encephalopathy market. We also progressed in our specialized sales force is positioned to effectively our effort to expand our presence in the inflammatory commercialize this patient-friendly formulation of this bowel disease market. On the marketing and sales side, widely-prescribed agent, if and when approved. we grew OSMOPREP® and MOVIPREP® to command a 25% We expect the product development success share of the prescription bowel cleansing market and we achieved during 2007 to be followed by commercial continued to grow XIFAXAN. On the business development success during 2008, as we anticipate receiving responses front we broadened our portfolio with the acquisitions of from the Food and Drug Administration during 2008 PEPCID OS® and metoclopramide-ZYDIS®.
    [Show full text]